South Korean biopharmaceutical company at Songdo in Incheon, founded in 2012 as a joint venture between Samsung Biologics and Biogen and wholly owned by Samsung Biologics since 2022. Develops and commercialises biosimilar medicines, with approved products referencing etanercept, infliximab, adalimumab, trastuzumab, bevacizumab, ranibizumab, aflibercept, ustekinumab and eculizumab among others, marketed worldwide through partners such as Organon and Biogen, and also works on novel biologics.
Keine Kommentare verfügbar.
Bewertung & Kommentar hinterlassen